FindTrial
Sign In

Retrospective study of polyene phosphatidylcholine injection based on propensity score matching method in the treatment of patients with hepatitis B related liver disease

Retrospective study of polyene phosphatidylcholine injection based on propensity score matching method in the treatment of patients with hepatitis B related liver disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051014
Enrollment
Unknown
Registered
2021-09-10
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hepatitis B related liver disease

Interventions

PPC group:Nil
Magnesium isoglycyrrhizinate group:Nil

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18~75 years; 2. Patients with hospitalization records of hepatitis B-related liver disease from October 1, 2018 to September 30, 2019; 3. In the treatment plan, only one of polyene phosphatidyl choline injection, magnesium isoglycyrrhizinate injection and reduced glutathione for injection, or any combination of the two, is used as the hepatoprotective drug; 4. The main research information required is complete.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to polyene phosphatidylcholine injection, magnesium isoglycyrrhizinate injection and reduced glutathione for injection; 2. Patients with contraindications to the three medicines: polyene phosphatidylcholine injection, magnesium isoglycyrrhizinate injection and reduced glutathione for injection.

Design outcomes

Primary

MeasureTime frame
ALT indicator;—

Countries

China

Contacts

Public ContactXu Jinghang

Peking University First Hospital

ddcatjh@sina.com+86 13661195941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026